A Review on Tafamidis to Treat a Genetic condition that affects Nerves and may lead to High Blood Pressure and Other Heart Problems
Abstract
Tafamidis, available under the brand names Vyndaqel and Vyndamax, is a medication used to help slow the progression of transthyretin amyloidosis in adults. This rare condition can be inherited, as seen in familial amyloid cardiomyopathy and familial amyloid polyneuropathy, or it can occur without a genetic link, such as in wild-type transthyretin amyloidosis (previously called senile systemic amyloidosis). The drug works by binding to the transthyretin protein and stabilizing its structure, which helps prevent it from breaking apart and forming amyloid deposits that can harm organs like the heart and nervous system. Tafamidis has been recognized by the U.S. Food and Drug Administration as a first-in-class therapy due to its novel mechanism of action.
Fields of Study & Subjects
Amyloidosis: Diagnosis
Treatment
Outcomes
Alzheimer's disease research and treatments
Prion Diseases and Protein Misfolding
Publication details
- Journal / source
- Asian Journal of Pharmaceutical Research
- Volume
- 16
- Issue
- 1
- Pages
- 83–83
- Publication date
- 22 January 2026
- Language
- EN